{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011509","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.699757+00:00","generated_at":"2026-06-04T07:09:21.073158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Matinas BioPharma reports 2023 net loss $22.9M; cash runway only through Q3 2024","bullets":["Revenue fell to $1.1M from $3.2M; net loss per share $0.11 vs $0.10 prior year.","Cash and equivalents $13.8M at Dec 31, 2023, down from $28.8M; company sees funding only through Q3 2024.","FDA agreed on design of single Phase 3 ORALTO trial for MAT2203 in invasive aspergillosis.","Compassionate use program: 19 patients enrolled; most with renal recovery after switching from AmBisome; 8 completed with complete resolution.","Preclinical LNC-docetaxel shows comparable efficacy to IV-docetaxel with no weight loss in mice."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011509","json":"https://secwatch.observer/filing/0001493152-24-011509.json","markdown":"https://secwatch.observer/filing/0001493152-24-011509.md","text":"https://secwatch.observer/filing/0001493152-24-011509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224011509/0001493152-24-011509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224011509/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:09:21.073158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cfb344b23c8c08bf65f504b9ab800e95f0cc77c6","claim":"Matinas BioPharma Holdings, Inc. reported financial results for for the year and quarter ended December 31, 2023.","evidence_excerpt":"On March 27, 2024, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the year and quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224011509/0001493152-24-011509-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the year and quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}